Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc (NQ: MNPR )

19.71 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Monopar Therapeutics Inc

< Previous 1 2 Next >
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
From Monopar Therapeutics Inc.
Via GlobeNewswire
MarketBeat Week in Review – 10/21- 10/25
Equities had a mixed week, but the tech-heavy NASDAQ powered to an all-time high; big tech earnings and key economic reports could bring more volatility 
Via MarketBeat
Topics Artificial Intelligence Economy Stocks
Exposures Artificial Intelligence Economy Interest Rates
Monopar Therapeutics Skyrockets 400% on Licensing Deal
Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug. 
Via MarketBeat
Exposures COVID-19
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar and NorthStar Amend & Extend Collaboration
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces CFO Succession
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS